PSTV PLUS THERAPEUTICS Inc.

2.85
-0.15  -5%
Previous Close 3
Open 3.01
52 Week Low 0.931
52 Week High 5.42
Market Cap $60,152,718
Shares 21,106,217
Float 21,106,033
Enterprise Value $63,657,148
Volume 472,034
Av. Daily Volume 930,162
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
DocePLUS (ATI-1123)
Platinum-sensitive small cell lung cancer
Phase 2
Phase 2
Phase 1 trial has completed.
Rhenium NanoLiposomes (ReSPECT)
Glioma
Phase 1/2
Phase 1/2
Phase 1 initial data presented at SNO Annual Meeting November 19, 2020.

Latest News

  1. – Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –

    – Completed sixth dosing cohort in ReSPECT™ December 2020 –

    – Management to host conference call today, Monday, February 22nd, at 5:00 p.m. ET –

    AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent business highlights.

    "In the second quarter of 2020, we in-licensed a promising new radiotherapeutic…

    – Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –

    – Completed sixth dosing cohort in ReSPECT™ December 2020 –

    – Management to host conference call today, Monday, February 22nd, at 5:00 p.m. ET –

    AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent business highlights.

    "In the second quarter of 2020, we in-licensed a promising new radiotherapeutic platform and portfolio of investigational drugs, then made substantial clinical progress for the lead compound and also moved additional opportunities closer to clinical phase," said Marc Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. "In 2021, we intend to make even greater progress advancing our CNS oncology portfolio through the development process and bringing it closer to a potential registrational clinical trial read out."

    Rhenium NanoLiposome (RNL™) Program - Background and 2020 Highlights

    The Company's lead investigational drug is RNL™, a radiotherapy in development for several rare cancer targets, including recurrent glioblastoma (GBM) in the U.S. multi-center ReSPECT™ Phase 1 dose-finding trial. RNL™ is designed to safely, effectively, and conveniently deliver a very high dose of radiation directly into the brain tumor compared to traditional external beam radiation therapy (EBRT). 2020 highlights for RNL™ include:

    • ReSPECT™ trial of RNL™ for recurrent glioblastoma supported by a multi-phase and multi-year financial grant from the U.S. National Institutes of Health/National Cancer Institute (NIH/NCI).
    • RNL™ received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of GBM.
    • Presented positive interim data from the first 15 patients, through Cohort 5, in the ReSPECT™ trial at the 2020 Society for Neuro-Oncology Annual Meeting (SNO 2020 E-poster).
    • Completed the 6th dose escalation cohort, with 18 total patients treated in ReSPECT™, with increases in both the RNL™ drug volume and radiation dose.
    • Thus far, RNL™ can be successfully delivered with up to 15 times the absorbed dose of radiation administered by standard EBRT without significant toxicity.
    • ReSPECT™ clinical trial expanded to two additional locations.
    • Established Clinical Advisory and Scientific Advisory Boards with leading experts in the fields of neurosurgery, neuro-oncology, preclinical drug development, and nanotechnology.

    Expected Upcoming Milestones and Events

    In upcoming quarters, the Company intends to focus on a number of additional business objectives and potential milestones:

    • Complete enrollment of the ReSPECT™ Phase 1 trial for RNL™ in recurrent glioblastoma.
    • Complete pivotal trial planning with FDA for RNL™ in recurrent glioblastoma.
    • Complete pre-IND meeting with the FDA, execute IND-enabling studies, if needed, and move into clinical trials for follow-on RNL™ indications, leptomeningeal metastases and pediatric brain cancer.
    • Continue development and evaluation of additional external and internal drug development candidates to expand the pipeline.
    • Continue partnership discussions for three clinical-stage injectable drugs: RNL™, DocePLUS™, and generic DoxoPLUS™.

    Fourth Quarter 2020 Financial Results

    • As of December 31, 2020, the Company's cash balance was $8.3 million, compared to $17.6 million as of December 31, 2019.
    • Net cash used in operating activities was $8.4 million for the year ended December 31, 2020, compared to net cash used in operating activities of $5.9 million during the same period in 2019.
    • During the second quarter of 2020, $5.0 million of the Oxford debt principal was paid down to a current principal balance of $4.3 million at December 31, 2020.
    • Net loss for full year 2020 was $8.2 million, or $(1.86) per share, compared to a net loss of $11.4 million, or $(8.27) per share (on a fully diluted basis including preferred stock), for full year 2019.

    Conference Call

    The Company will hold a conference call and live audio webcast at 5:00 p.m. Eastern Time today to discuss its financial results and provide a general business update.

    Event: Plus Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast
    Date: Monday, February 22, 2021
    Time: 5:00 p.m. Eastern Time
    Live Call:877-402-3914 (toll free); 631-865-5294 (Intl.); Conference ID: 6206747

    The webcast can be accessed live via the investor section of the Plus Therapeutics website at ir.plustherapeutics.com/events and will be available for replay beginning two hours after the conclusion of the conference call.

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at www.PlusTherapeutics.com and www.respect-trials.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "will," "believe," "plan," "can," "enable," "design," "intend," "potential," "expect," "estimate," "project," "prospect," "target," "focus," "anticipate," "could," "should," and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the design and potential of the Plus Therapeutics portfolio to reformulate, deliver and commercialize multiple novel, proprietary drugs targeting rare cancers and other diseases and to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs; the potential of the Company's new, in-licensed portfolio of investigational drugs; the Company's intent to advance its CNS oncology portfolio through the clinical development process; the ability of RNL to safely, effectively and conveniently deliver a very high dose of radiation greater than traditional EBRT directly into the brain tumor; and the Company's anticipated milestones and events, including with respect to enrollment, pivotal trial planning, IND process, and clinical phase plans for RNL, pipeline expansion through additional drug development candidates, and partnership discussions for RNL, DocePLUS and DoxoPLUS. The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; the early stage of the Company's product candidates and therapies, the results of its research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's history of losses; the Company's need for, and ability to raise, additional cash or obtain other sources of funding in the immediate future; the Company's ability to: (a) obtain and maintain regulatory approvals, (b) continue as a going concern, (c) remain listed on the Nasdaq Capital Market, (d) to obtain or maintain sufficient levels of reimbursement for its tests, and (d) to repay or refinance some or all of its outstanding indebtedness; the outcome of the Company's partnering/licensing efforts; market and economic conditions; the impact of the COVID-19 pandemic on the Company and the effectiveness of the efforts it has taken or may take in the future in response thereto; and additional risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.





    PLUS THERAPEUTICS, INC.

    CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and par value data)

      As of December 31, 
      2020  2019 
    Assets        
    Current assets:        
    Cash and cash equivalents $8,346  $17,552 
    Accounts receivable     1,169 
    Restricted cash     40 
    Inventories, net     107 
    Other current assets  829   957 
    Total current assets  9,175   19,825 
             
    Property and equipment, net  1,820   2,179 
    Operating lease right-use-of assets  636   781 
    Goodwill  372   372 
    Intangible assets, net  86    
    Other assets  16   72 
    Total assets $12,105  $23,229 
    Liabilities and Stockholders' Equity        
    Current liabilities:        
    Accounts payable and accrued expenses $2,081  $3,279 
    Operating lease liability  123   147 
    Term loan obligation, net of discount  6,335   11,060 
    Total current liabilities  8,539   14,486 
             
    Noncurrent operating lease liability  528   646 
    Warrant liability  7   6,929 
    Other noncurrent liabilities     8 
    Total liabilities  9,074   22,069 
             
    Commitments and contingencies        
             
    Stockholders' equity:        
    Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,954 and 1,959 shares issued and outstanding in 2020 and 2019, respectively      
    Common stock, $0.001 par value; 100,000,000 shares authorized; 6,749,028 and 3,880,588 shares issued and outstanding in 2020 and 2019, respectively  7   4 
    Additional paid-in capital  436,535   426,426 
    Accumulated deficit  (433,511)  (425,270)
    Total stockholders' equity  3,031   1,160 
    Total liabilities and stockholders' equity $12,105  $23,229 





    PLUS THERAPEUTICS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (in thousands, except share and per share data)

      For the Years Ended December 31, 
      2020  2019 
    Development revenue:        
    Government contracts and other $303  $6,998 
       303   6,998 
    Operating expenses:        
    Research and development  2,700   5,365 
    In process research and development acquired from NanoTx  781    
    General and administrative  6,406   5,290 
    Total operating expenses  9,887   10,655 
    Operating loss  (9,584)  (3,657)
             
    Other income (expense):        
    Interest income  50   55 
    Interest expense  (1,107)  (1,855)
    Change in fair value of liability instruments  2,400   3,407 
    Issuance cost of warrants     (1,233)
    Total other expense  1,343   374 
    Loss from continuing operations $(8,241) $(3,283)
    Loss from discontinued operations     (7,604)
    Net loss $(8,241) $(10,887)
             
    Loss from continuing operations $(8,241) $(3,283)
    Beneficial conversion feature for convertible preferred stock     (554)
    Net loss allocable to common stockholders - continuing operations $(8,241) $(3,837)
    Net loss allocable to common stockholders - discontinued operations  -   (7,604)
    Net loss allocable to common stockholders $(8,241) $(11,441)
    Basic and diluted net loss per share attributable to common stockholders – continuing operations $(1.86) $(2.77)
    Basic and diluted net loss per share attributable to common stockholders - discontinued operations  -   (5.49)
    Net loss per share, basic and diluted $(1.86) $(8.27)
             
    Basic and diluted weighted average shares used in calculating net loss per share

    attributable to common stockholders
      4,427,835   1,384,012 





    PLUS THERAPEUTICS, INC.

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

      For the Years Ended December 31, 
      2020  2019 
    Cash flows used in operating activities:        
    Net loss $(8,241) $(10,887)
    Adjustments to reconcile net loss to net cash used in operating activities:        
    Depreciation and amortization  366   896 
    Amortization of deferred financing costs and debt discount  584   550 
    In process research and development acquired from NanoTx Therapeutics  781    
    Change in fair value of liability instruments  (2,400)  (3,407)
    Share-based compensation expense  247   127 
    Inventory write off  107    
    Noncash lease expense  3   12 
    Loss on sale of business     6,508 
    Allocation of issuance cost associated with warrants     1,233 
    Increases (decreases) in cash caused by changes in operating assets and liabilities:        
    Accounts receivable  1,169   (1,203)
    Inventories     259 
    Other current assets  126   (211)
    Other assets  58   263 
    Accounts payable and accrued expenses  (1,234)  (28)
    Deferred revenue     29 
    Other long-term liabilities     (47)
    Net cash used in operating activities  (8,434)  (5,906)
             
    Cash flows from (used in) investing activities:        
    Purchases of property and equipment  (93)  (67)
    In process research and development acquired from NanoTx Therapeutics  (400)   
    Proceeds from sale of business     5,637 
    Net cash provided by (used in) investing activities  (493)  5,570 
             
    Cash flows from financing activities:        
    Principal payments of long-term obligations  (5,307)  (3,692)
    Payment of financing lease liability  (117)  (131)
    Proceeds from exercise of warrants  1,098   490 
    Proceeds from sale of common stock  4,007   15,964 
    Net cash (used in) provided by financing activities  (319)  12,631 
    Effect of exchange rate changes on cash and cash equivalents     (4)
    Net increase (decrease) in cash and cash equivalents  (9,246)  12,291 
    Cash, cash equivalents, and restricted cash at beginning of period  17,592   5,301 
    Cash, cash equivalents, and restricted cash at end of period $8,346  $17,592 
             
    Supplemental disclosure of cash flows information:        
    Cash paid during period for:        
    Interest $567  $1,188 
    Supplemental schedule of non-cash investing and financing activities:        
    Issuance costs paid in common stock $463  $ 
    Common stock issued in payment for in process research and development $381  $ 
    Unpaid offering cost $125  $ 
    Proceeds from sales of business, net, paid directly to lender for principal payment of long-term obligations $  $3,050 
    Offering cost paid in warrants $  $213 
    Reclassification of warrants upon exercise from liability to equity $4,504  $794 
    Fair value of Convertible Preferred Stock beneficial conversion feature $  $554 
             

    Investor Contact

    Peter Vozzo

    Westwicke/ICR

    (443) 377-4767

    Media Contact

    Terri Clevenger

    Westwicke/ICR

    (203) 856-4326



    Primary Logo

    View Full Article Hide Full Article
  2. AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full year 2020 financial results on Monday, February 22, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

    A live webcast will be available at ir.plustherapeutics.com/events

    Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior…

    AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full year 2020 financial results on Monday, February 22, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

    A live webcast will be available at ir.plustherapeutics.com/events

    Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

    Conference dial-in:877-402-3914
    International dial-in:631-865-5294
    Conference ID:6206747
    Conference Call Name:Plus Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call

    Following the live call, a replay will be available on the Company's website under the 'Investor Relations' section. The webcast will be available on the Company's website for 90 days following the live call.

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains certain statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company's potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company's potential to develop drug candidates currently in its product pipeline; and the Company's potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; and the risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

    Investor Contact

    Peter Vozzo

    Westwicke/ICR

    (443) 377-4767

    Media Contact

    Terri Clevenger

    Westwicke/ICR

    (203) 856-4326



    Primary Logo

    View Full Article Hide Full Article
  3. AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO CEO & Investor Digital Conference being held February 16-18, 2021.

    The Company's presentation will be made through the BIO CEO & Investor Digital Conference website and available on demand to registered participants during the conference at https://www.bio.org/events/bio-ceo-investor-digital-conference/company-presentations. Subsequent to the conference, the presentation will…

    AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO CEO & Investor Digital Conference being held February 16-18, 2021.

    The Company's presentation will be made through the BIO CEO & Investor Digital Conference website and available on demand to registered participants during the conference at https://www.bio.org/events/bio-ceo-investor-digital-conference/company-presentations. Subsequent to the conference, the presentation will be made available under the ‘Events' tab of the Investor Relations section of the Plus Therapeutics website at www.plustherapeutics.com.

    In December, BIO and voter participants named Plus Therapeutics as this year's Public Therapeutic Company "Buzz of BIO", recognizing the Company's promising work developing novel therapies for rare and difficult to treat cancers, such as recurrent glioblastoma.     

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains certain statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company's potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company's potential to develop drug candidates currently in its product pipeline; and the Company's potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; and the risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

    Investor Contact

    Peter Vozzo

    Westwicke/ICR

    (443) 377-4767

    Media Contact

    Terri Clevenger

    Westwicke/ICR

    (203) 856-4326

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c7fde70-34fd-4f98-8dc5-f5f97d3f89bc



    Primary Logo

    View Full Article Hide Full Article
  4. AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage company focused on making a positive impact on patients' lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences.

    EventH.C. Wainwright BioConnect Conference
    DateJanuary 11-14, 2021
    TimePresentation available on demand January 11-14, 2021
      
    EventBiotech Showcase 2021
    DateJanuary 11-15, 2021
      
    EventICR Conference 2021
    DateThursday, January 14, 2021
    Time1:45 p.m. ET

    Investors interested in arranging a meeting with the Company's management during the ICR Conference 2021 should contact the conference coordinator or

    AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage company focused on making a positive impact on patients' lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences.

    EventH.C. Wainwright BioConnect Conference
    DateJanuary 11-14, 2021
    TimePresentation available on demand January 11-14, 2021
      
    EventBiotech Showcase 2021
    DateJanuary 11-15, 2021
      
    EventICR Conference 2021
    DateThursday, January 14, 2021
    Time1:45 p.m. ET

    Investors interested in arranging a meeting with the Company's management during the ICR Conference 2021 should contact the conference coordinator or . Webcasts of the H.C. Wainwright and ICR conferences presentations will be available under the ‘Events' tab of the Investor Relations section of the Plus Therapeutics website at www.plustherapeutics.com.

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains certain statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company's potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company's potential to develop drug candidates currently in its product pipeline; and the Company's potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; and the risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

    Investor Contact

    Peter Vozzo

    Westwicke/ICR

    (443) 377-4767

    Media Contact

    Terri Clevenger

    Westwicke/ICR

    (203) 856-4326



    Primary Logo

    View Full Article Hide Full Article
  5. AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial evaluating the Company's lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).

    The sixth cohort of the ReSPECT trial included an increase in both the RNL drug volume and the radiation dose to 8.8 milliliters and 22.3 millicuries, respectively. RNL is designed to safely, effectively and conveniently deliver a very high dose of radiation potentially up to 15 times…

    AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial evaluating the Company's lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).

    The sixth cohort of the ReSPECT trial included an increase in both the RNL drug volume and the radiation dose to 8.8 milliliters and 22.3 millicuries, respectively. RNL is designed to safely, effectively and conveniently deliver a very high dose of radiation potentially up to 15 times greater than traditional external beam radiation therapy.

    Eighteen patients with recurrent GBM thus far have been treated in the ReSPECT trial. This trial is supported by the U.S. National Institutes of Health/National Cancer Institute at three trial sites in the U.S., including UT Health Science Center San Antonio and UT Southwestern Medical Center.

    "The dose escalation design in ReSPECT permits both increases in drug volume and the radiation dose of RNL," said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. "This scheme is important as it allows us to potentially better target those malignant cells at the tumor margin that may be the source of future disease progression."

    As previously disclosed, the U.S. Food and Drug Administration has granted both Orphan Drug designation and Fast Track designation to RNL for the treatment of patients with GBM. Additional details about the ReSPECT trial are available at clinicaltrials.gov (NCT01906385). Interim data from ReSPECT was disclosed in November 2020 at the Society of Neuro-Oncology Annual Meeting and showed that RNL was well-tolerated, with no dose-limiting toxicity observed in the first 15 patients enrolled in the trial.

    About Plus Therapeutics, Inc.

    Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains certain statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company's potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company's potential to develop drug candidates currently in its product pipeline; and the Company's potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA's accelerated regulatory pathways; and the risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

    Investor Contact

    Peter Vozzo

    Westwicke/ICR

    (443) 377-4767

     

    Media Contact

    Terri Clevenger

    Westwicke/ICR

    (203) 856-4326

     

     



    Primary Logo

    View Full Article Hide Full Article
View All PLUS THERAPEUTICS Inc. News